Transcranial Magnetic Stimulation (TMS) Effects Using Magnetoencephalography (MEG) Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

10 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-03-21

Study Completion Date

2026-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alcohol use disorder (AUD) is a complex chronic brain disease characterized by compulsive alcohol use, loss of control over drinking, and negative emotional states. Extensive research has identified the general neural circuitry underlying AUD. There is an exciting opportunity to intervene in AUD using neuromodulation. Transcranial magnetic stimulation (TMS) offers a non-invasive method to modulate brain activity, making it a promising tool for investigating, modulating, and potentially treating AUD. However, the precise effects of TMS on neural circuits involved in AUD and the mechanisms underlying these effects must first be understood. Magnetoencephalography (MEG) is a neuroimaging method that provides direct measurement of brain activity within neural circuits with high temporal resolution. Critically, MEG can measure brain activity in a wide range of frequencies that are consistent with those targeted by TMS. The goal of this proposal is therefore to collect preliminary and feasibility data to support a future NIH grant application that would use MEG to investigate TMS effects in individuals with AUD (iAUD).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Transcranial Magnetic Stimulation (TMS) Treatment for Alcohol Use Disorder

NCT03969251

Alcoholism

UNKNOWN NA

Effect of Repetitive TMS on Executive Function in Alcohol Use Disorder

NCT05997212

Alcohol Use Disorder

RECRUITING NA

Assessing the Impact of Deep TMS Neuromodulation on Neural Circuits Associated With Alcohol Use Disorder

NCT06949423

Alcohol Use Disorder (AUD) Transcranial Magnetic Stimilation

NOT_YET_RECRUITING NA

Examining the Effectiveness of Deep TMS in Veterans With Alcohol Use Disorder

NCT04927364

Alcohol Use Disorder (AUD) Transcranial Magnetic Stimulation

COMPLETED NA

TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD)

NCT07171359

Alcohol Use Disorder Opioid Use Disorder

NOT_YET_RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This proposal uses a mixed, between-group, within-subject design. The study will investigate the acute effects of different TMS pulse sequences in participants without AUD (non-AUD), and compare active/sham iTBS across non-AUD and AUD. On each study day, participants will complete a pre-TMS baseline MEG scan (10 min resting state), followed by a TMS pulse sequence, then complete 3 more MEG scans (immediately post-TMS, 1 hour post-TMS, and 2 hours post-TMS). Each TMS pulse sequence will be administered on a separate day and will be matched by the number of pulses administered (1200 pulses) and the total duration of administration time (20 min). The sham condition will control for auditory and sensory side effects associated with TMS. TMS will be applied to the left DLPFC, identified by the EEG F3 coordinate. Participants will either complete 4 study visits (n = 5) and receive 1 Hz, 10 Hz, iTBS, and sham, each on a separate day; or participants will complete 2 study visits (n = 5) and receive iTBS and sham, each on a separate day. Participants will also receive a structural MRI scan in order to map the MEG outcome data onto their own anatomical brain image.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Use Disorder Alcohol Dependence Alcohol Consumption

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Caregivers

Intervention Type DEVICE

Participants will receive sham iTBS

Active iTBS

Intervention Type DEVICE

Participants will receive active iTBS

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Sham iTBS

Participants will receive sham iTBS

Intervention Type DEVICE

Active iTBS

Participants will receive active iTBS

Intervention Type DEVICE

10 Hz TMS

Participant will receive 10 Hz TMS

Intervention Type DEVICE

1 Hz TMS

Participant will receive 1 Hz TMS

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnostic and Statistical Manual of Mental Disorders (DSM-5) score for AUD = 0
* Alcohol Use Disorders Identification Test (AUDIT) score ≤ 7
* Is not a heavy alcohol consumer

* DSM-5 score for AUD ≥ 3
* AUDIT score ≥ 8
* Is a heavy alcohol consumer

Exclusion Criteria

* Current substance use disorder other than alcohol use disorder and/or frequent use of non-prescribed psychoactive substances.
* Current serious psychiatric disorder, and/or any history of a psychotic disorder
* Any health problem that would interfere with the study or could be aggravated by study procedures (e.g., history of migraines, claustrophobia).
* Is currently taking or initiates a medication known to affect alcohol intake and/or craving.
* History of traumatic brain injury resulting in hospitalization, loss of consciousness, and/or having ever been informed he/she has an epidural, subdural, or subarachnoid hemorrhage.
* Does not meet safety criteria for TMS or MRI.
* Females of childbearing potential who are pregnant (by urine HCG), planning to become pregnant, nursing, or who are not using a reliable form of birth control.
* Is at an elevated risk of seizure (i.e. has a history of seizures, is currently prescribed medications known to lower seizure threshold and has had a change in their medication).
* Clinical Intake Withdrawal Assessment (CIWA\>5) (to prevent delivering TMS to individuals in withdrawal).
* Not able to read and understand questionnaires, assessments, and/or the informed consent.

Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes